(Q39182864)

English

Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer

scientific article published on 8 March 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

author name string

Areumnuri Kim

1

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Jung-Eun Lee

2

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Seung-Sook Lee

3

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Cherin Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Sun-Joo Lee

5

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Won-Suk Jang

6

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Sunhoo Park

7

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

language of work or name

0 references

publication date

8 March 2013

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

133

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

984-996

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Predictive molecular classifiers in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Phosphatidylinositol-3-OH kinase as a direct target of Ras

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Ras, PI(3)K and mTOR signalling controls tumour cell growth

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

The prevalence of PIK3CA mutations in gastric and colon cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

The phosphoinositide 3-kinase pathway

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Activation of the PI3K/Akt pathway and chemotherapeutic resistance

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

NVP-BEZ235 as a new therapeutic option for sarcomas.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Resist or die: FOXO transcription factors determine the cellular response to chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

G1 cell-cycle control and cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Identification and characterization of BH3 domain protein Bim and its isoforms in human hepatocellular carcinomas.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Differentiation-related gene-1 decreases Bim stability by proteasome-mediated degradation

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Structure, regulation and function of PKB/AKT--a major therapeutic target

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Role of Akt/protein kinase B in metabolism.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE(2) signalling in colorectal adenoma cells.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Bim: a novel member of the Bcl-2 family that promotes apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Chronic Protein Kinase B (PKB/c-akt) Activation Leads to Apoptosis Induced by Oxidative Stress-Mediated Foxo3a Transcriptional Up-regulation

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28073

21 January 2018

Identifiers

10.1002/IJC.28073

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39182864&oldid=1812057740"